Navidea Biopharmaceuticals (NAVB) Competitors $0.0001 0.00 (-80.00%) As of 09/18/2025 01:05 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock NAVB vs. VINC, NCNA, SYRS, VRPX, SCPS, ARDS, EVLO, CMRA, GNCAQ, and GNCAShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Vincerx Pharma (VINC), NuCana (NCNA), Syros Pharmaceuticals (SYRS), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Its Competitors Vincerx Pharma NuCana Syros Pharmaceuticals Virpax Pharmaceuticals Scopus BioPharma Aridis Pharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Vincerx Pharma (NASDAQ:VINC) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership. Which has more volatility & risk, VINC or NAVB? Vincerx Pharma has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Which has stronger valuation & earnings, VINC or NAVB? Navidea Biopharmaceuticals has higher revenue and earnings than Vincerx Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVincerx PharmaN/AN/A-$40.16M-$20.600.00Navidea Biopharmaceuticals$8.13K1.23-$15.18MN/AN/A Does the media favor VINC or NAVB? In the previous week, Vincerx Pharma's average media sentiment score of 1.00 beat Navidea Biopharmaceuticals' score of 0.00 indicating that Vincerx Pharma is being referred to more favorably in the media. Company Overall Sentiment Vincerx Pharma Positive Navidea Biopharmaceuticals Neutral Do analysts prefer VINC or NAVB? Vincerx Pharma presently has a consensus target price of $40.00, indicating a potential upside of 99,900.00%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe Vincerx Pharma is more favorable than Navidea Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in VINC or NAVB? 44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is VINC or NAVB more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Vincerx PharmaN/A -248.33% -132.73% Navidea Biopharmaceuticals N/A N/A N/A SummaryNavidea Biopharmaceuticals beats Vincerx Pharma on 6 of the 11 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$10K$22.63M$5.78B$21.54BDividend YieldN/AN/A5.74%3.51%P/E RatioN/AN/A76.7730.17Price / Sales1.2317.44515.7875.21Price / CashN/AN/A37.1724.62Price / BookN/AN/A13.484.58Net Income-$15.18M-$19.12M$3.29B$1.00B7 Day PerformanceN/A-4.88%1.55%1.52%1 Month PerformanceN/A-7.27%6.80%5.96%1 Year PerformanceN/A-1.72%77.33%14.24% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00-80.0%N/A-90.0%$10K$8.13K0.0010VINCVincerx Pharma3.4862 of 5 stars$0.04-3.5%$40.00+104,338.6%-99.7%$200KN/A0.0060Positive NewsNCNANuCana0.828 of 5 stars$2.92+1.0%N/A-99.4%$88KN/A0.0030SYRSSyros Pharmaceuticals4.3001 of 5 stars$0.00-50.0%$1.00+90,809.1%-100.0%$30K$386K0.00120Positive NewsGap DownVRPXVirpax Pharmaceuticals0.2107 of 5 stars$0.01-9.8%N/A-99.9%$14KN/A0.007Gap DownSCPSScopus BioPharmaN/A$0.00-25.0%N/A+0.0%$13KN/A0.009Gap DownARDSAridis PharmaceuticalsN/A$0.00-60.0%N/AN/A$11KN/A0.0030High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Options VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070 Related Companies and Tools Related Companies Vincerx Pharma Competitors NuCana Competitors Syros Pharmaceuticals Competitors Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Aridis Pharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAVB Stock Alerts